Medexus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on oncology, hematology, and rheumatology in North America. Its strengths include a solid gross margin of 63.8% and a manageable debt-to-equity ratio of 0.55, indicating financial stability. However, concerns arise from a low net margin of 1.9% and a relatively low return on equity at 1.1%, suggesting profitability challenges. Despite high margins, the market cap of $155.24M and a recent price decline of 0.80% indicate potential valuation issues that investors should monitor.
Loading financial metrics...
Debt of $26.3M is 4.9x the company's cash position of $5.3M.
Company went from $806K profit to $-2.4M loss compared to last year.
Both gross margin (+4.5pp) and operating margin (+1.4pp) are expanding simultaneously, indicating the company is scaling profitably.
Gross margin improvement of 4.5pp suggests operational efficiency gains.
Strong gross margin of 57.0% reflects healthy unit economics.
Low debt-to-revenue ratio of 25.4% indicates conservative financial management.
Strong free cash flow margin of 13.8% provides substantial resources for dividends, buybacks, or reinvestment.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2027-Q1 (June 30, 2026)